Comparing Vyndamax vs Vyndaqel
| Vyndamax (tafamidis) | Vyndaqel (tafamidis) |
|
|---|
| Vyndamax (tafamidis) | Vyndaqel (tafamidis) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vyndamax may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vyndaqel may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Vyndamax (tafamidis) | More about Vyndaqel (tafamidis) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Vyndamax has an average rating of 8.0 out of 10 from a total of 7 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 0% reported a negative effect. |
Vyndaqel has an average rating of 7.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Vyndamax side effects |
View all Vyndaqel side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Vyndamax prices |
View all Vyndaqel prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other tafamidis brands include: Vyndaqel | Other tafamidis brands include: Vyndamax | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
59 hours |
59 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 33 drugs are known to interact with Vyndamax:
|
A total of 33 drugs are known to interact with Vyndaqel:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
May 03, 2019 |
May 03, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.